Oropharyngeal Carcinoma – Causes, Symptoms & Treatment

What is Oropharyngeal Carcinoma?

Oropharyngeal carcinoma is a malignant (cancerous) tumor that develops in the oropharynx – the middle part of the throat connecting the oral cavity to the larynx. Structures commonly affected include the palatine tonsils, the base of the tongue, the soft palate, the uvula, and the posterior pharyngeal wall. Histologically, the vast majority of cases are squamous cell carcinomas.

Over recent decades, the incidence of oropharyngeal carcinoma has risen significantly in many Western countries, largely driven by the increasing role of human papillomavirus (HPV) – particularly HPV subtype 16 – as a causative agent.

Causes and Risk Factors

Two main pathways of development are recognized:

• HPV-associated oropharyngeal carcinoma: Caused by infection with high-risk HPV types, most commonly HPV-16. This subtype tends to affect younger patients without classic risk factors and is generally associated with a more favorable prognosis.
• Non-HPV-associated oropharyngeal carcinoma: Strongly linked to long-term tobacco use (smoking or chewing tobacco) and excessive alcohol consumption. The combination of both factors significantly amplifies the risk.

Additional risk factors include:

• Chronic mucosal irritation
• Poor oral hygiene
• Nutritional deficiencies
• Immunosuppression (e.g., post-transplant or in HIV infection)

Symptoms

Early-stage oropharyngeal carcinoma often presents with nonspecific symptoms, which can delay diagnosis. Common symptoms include:

• Persistent sore throat or difficulty swallowing (dysphagia)
• Sensation of a foreign body in the throat
• Hoarseness or changes in voice quality
• Pain when speaking or swallowing
• Unexplained weight loss
• Palpable enlarged lymph nodes in the neck (often the first sign)
• Bleeding in the mouth or throat
• Bad breath (halitosis)

Diagnosis

Diagnosis is established through a stepwise approach:

Clinical Examination

A physician or ENT (ear, nose, and throat) specialist examines the oral cavity and pharynx by direct inspection and palpation. Enlarged cervical lymph nodes are assessed manually.

Endoscopy

Flexible or rigid endoscopy allows detailed visualization of the oropharynx and adjacent structures, enabling direct assessment of suspicious lesions.

Biopsy and Histology

A tissue biopsy from the suspicious area is essential to confirm the diagnosis. The sample is examined histologically for cancer cells. Simultaneously, HPV status (e.g., via p16 immunohistochemistry) is determined, as it significantly influences prognosis and treatment planning.

Imaging

To assess the extent of the tumor and lymph node involvement, the following imaging modalities are used:

• Computed tomography (CT) of the neck, chest, and abdomen
• Magnetic resonance imaging (MRI) for detailed soft-tissue assessment
• Positron emission tomography (PET-CT) to detect distant metastases

Staging

Tumor extent is classified according to the TNM system (Tumor, Nodes, Metastases), which guides treatment decisions.

Treatment

Treatment depends on the tumor stage, HPV status, the general health of the patient, and the treatment goal (curative or palliative). Decisions are ideally made by a multidisciplinary tumor board.

Surgery

In early stages, the tumor can often be removed via transoral resection (e.g., transoral robotic surgery, TORS) or open surgery. Surgical removal of cervical lymph nodes (neck dissection) is commonly performed simultaneously.

Radiation Therapy

Radiotherapy may be used as a standalone treatment or in combination with chemotherapy. Modern techniques such as intensity-modulated radiation therapy (IMRT) allow precise tumor targeting while minimizing damage to surrounding healthy tissue.

Chemotherapy and Chemoradiation

For locally advanced tumors, concurrent chemoradiotherapy (typically with cisplatin) is frequently employed to enhance the effectiveness of radiation.

Immunotherapy and Targeted Therapy

In recurrent or metastatic disease, immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) or the EGFR-targeting antibody cetuximab may be used.

Prognosis

Prognosis depends strongly on tumor stage and HPV status. HPV-positive oropharyngeal carcinomas carry a significantly better prognosis with higher cure rates compared to HPV-negative tumors. Five-year survival rates for early-stage disease exceed 70–80%, while rates for advanced-stage disease are considerably lower.

Prevention

Effective measures to reduce the risk of oropharyngeal carcinoma include:

• HPV vaccination: Vaccination against HPV (recommended for children and adolescents of all genders) can substantially reduce the risk of HPV-associated oropharyngeal carcinoma.
• Avoiding tobacco and alcohol
• Maintaining good oral hygiene and attending regular dental check-ups
• Regular ENT screening for individuals with persistent symptoms or risk factors

References

1. Leitlinienprogramm Onkologie (German Cancer Society, AWMF): S3 Guideline on Oral Cavity and Oropharyngeal Carcinomas, 2021. Available at: https://www.leitlinienprogramm-onkologie.de
2. Ferlay J et al. – Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
3. Gillison ML et al. – Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407-420.